Q1 Earnings Forecast for MREO Issued By Leerink Partnrs

Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earnings per share of $0.07 for the quarter. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group's Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.03).

Several other brokerages have also recently weighed in on MREO. Needham & Company LLC reissued a "buy" rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Wednesday, March 26th. Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday, March 18th. Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an "outperform" rating and a $10.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Mereo BioPharma Group in a research note on Thursday, March 27th. They issued an "overweight" rating and a $7.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of Mereo BioPharma Group in a research note on Friday, December 6th. They set a "buy" rating and a $7.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $7.71.

Remove Ads

Mereo BioPharma Group Price Performance

Shares of Mereo BioPharma Group stock traded down $0.16 during trading hours on Monday, reaching $2.21. The company's stock had a trading volume of 1,187,376 shares, compared to its average volume of 1,015,438. Mereo BioPharma Group has a one year low of $2.11 and a one year high of $5.02. The firm has a 50 day moving average price of $2.66 and a 200-day moving average price of $3.43. The stock has a market cap of $342.87 million, a P/E ratio of -36.83 and a beta of 0.71.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. purchased a new stake in Mereo BioPharma Group in the 4th quarter valued at about $37,000. Jump Financial LLC bought a new stake in shares of Mereo BioPharma Group during the fourth quarter valued at approximately $39,000. Sheets Smith Investment Management purchased a new stake in shares of Mereo BioPharma Group in the fourth quarter valued at approximately $59,000. Virtus ETF Advisers LLC bought a new position in Mereo BioPharma Group in the fourth quarter worth approximately $67,000. Finally, Avanza Fonder AB purchased a new position in Mereo BioPharma Group during the 4th quarter worth $69,000. 62.83% of the stock is currently owned by institutional investors.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.